ABSK-091
- Generic Name
- ABSK-091
- Drug Type
- Small Molecule
- Chemical Formula
- C26H33N5O3
- CAS Number
- 1035270-39-3
A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Abbisko Therapeutics Co, Ltd
- Target Recruit Count
- 80
- Registration Number
- NCT05775874
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547
- First Posted Date
- 2021-10-21
- Last Posted Date
- 2021-10-21
- Lead Sponsor
- Abbisko Therapeutics Co, Ltd
- Target Recruit Count
- 108
- Registration Number
- NCT05086666
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China
Treatment With AZD4547 for Recurrent Malignant Glioma Expressing FGFR-TACC Gene Fusion"
- Conditions
- Recurrent IDHwt Gliomas With FGFR3-TACC3 FusionRecurrent IDHwt Gliomas With FGFR1-TACC1 Fusion
- Interventions
- First Posted Date
- 2016-07-06
- Last Posted Date
- 2019-05-29
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 14
- Registration Number
- NCT02824133
- Locations
- 🇫🇷
Neuro onsology unit - Groupe Hospitalier Pitié-Salpêtrière, Paris, France
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
- Conditions
- AdenocarcinomaNon-Small Cell Lung CancerCarcinoma, Squamous Cell
- Interventions
- First Posted Date
- 2016-01-27
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 423
- Registration Number
- NCT02664935
- Locations
- 🇬🇧
Royal Devon and Exeter Hospital, Exeter, United Kingdom
🇬🇧University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom
🇬🇧Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer
- Conditions
- Muscle Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2015-09-11
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 117
- Registration Number
- NCT02546661
- Locations
- 🇬🇧
Research Site, Southampton, United Kingdom
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
- Conditions
- Advanced LymphomaAdvanced Malignant Solid NeoplasmBladder CarcinomaBreast CarcinomaCervical CarcinomaColon CarcinomaColorectal CarcinomaEndometrial CarcinomaEsophageal CarcinomaExocrine Pancreas Carcinoma
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Computed TomographyOther: Cytology Specimen Collection ProcedureProcedure: Radiologic ExaminationProcedure: Multigated Acquisition ScanProcedure: Echocardiography TestOther: Laboratory Biomarker AnalysisProcedure: Magnetic Resonance ImagingProcedure: Radionuclide Imaging
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 6452
- Registration Number
- NCT02465060
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸Thomas Hospital, Fairhope, Alabama, United States
🇺🇸Mobile Infirmary Medical Center, Mobile, Alabama, United States
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- Drug: AnthracyclinesDrug: TaxanesDrug: DNA intercalators
- First Posted Date
- 2014-11-24
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 1460
- Registration Number
- NCT02299999
- Locations
- 🇫🇷
Hopitaux Universitaire de Strasbourg - Hopital Civil, Strasbourg, France
🇫🇷Institut Claudius Regaud, Toulouse, France
🇫🇷Hopitaux Du Leman, Thonon-les-Bains, France
SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients
- Conditions
- Non-small Cell Lung Cancer Metastatic
- Interventions
- Drug: Standard maintenance for squamous NSCLC
- First Posted Date
- 2014-04-17
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 999
- Registration Number
- NCT02117167
- Locations
- 🇫🇷
Hôpital Avicenne, Bobigny, France
🇫🇷Institut Bergonié, Bordeaux, France
🇫🇷Institut Paoli Calmettes, Marseille, France
Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer
- Conditions
- Squamous Cell Lung CancerRecurrent Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2013-04-05
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 2
- Registration Number
- NCT01824901
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours
- Conditions
- Squamous Cell Carcinoma of the LungGastric CancerOesophageal CancerBreast Cancer
- Interventions
- First Posted Date
- 2013-02-21
- Last Posted Date
- 2013-03-15
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Target Recruit Count
- 48
- Registration Number
- NCT01795768
- Locations
- 🇬🇧
Royal Marsden NHS Foundation Trust, London and Surrey, Surrey, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.